title: Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma.
authors.affiliation: Department of Internal Medicine, Cedars-Sinai Med Ctr, Los Angeles, CA, USA. martina.zalom@cshs.org
authors.forename: Martina
authors.initials: M
authors.lastname: Zalom
authors.forename: Michael
authors.initials: M
authors.lastname: Lill
authors.forename: Dusan
authors.initials: D
authors.lastname: Lukic
authors.forename: Bonnie L
authors.initials: BL
authors.lastname: Balzer
authors.forename: Stephen
authors.initials: S
authors.lastname: Lim
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D003131:Combined Modality Therapy; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox